Rock Springs Capital Management’s Beam Therapeutics BEAM Stock Holding History

Rock Springs Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,020	Closed	-$2.93M	–	95
2025 Q1	$2.93M	Sell	150,020 -102,203	-41%	-$2.68M	0.17%	73
2024 Q4	$6.26M	Buy	252,223 +2,300	+0.9%	+$58.7K	0.24%	71
2024 Q3	$6.12M	Hold	249,923	–	–	0.2%	78
2024 Q2	$5.86M	Buy	249,923 +102,413	+69%	+$2.52M	0.18%	80
2024 Q1	$4.87M	Buy	147,510 +36,080	+32%	+$1.12M	0.12%	92
2023 Q4	$3.03M	Hold	111,430	–	–	0.07%	89
2023 Q3	$2.68M	Hold	111,430	–	–	0.07%	94
2023 Q2	$3.56M	Hold	111,430	–	–	0.08%	95
2023 Q1	$3.41M	Hold	111,430	–	–	0.08%	98
2022 Q4	$4.36M	Hold	111,430	–	–	0.1%	92
2022 Q3	$5.31M	Hold	111,430	–	–	0.14%	94
2022 Q2	$4.31M	Buy	+111,430	New	+$4.43M	0.13%	98

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Rock Springs Capital Management's BEAM Position: Q2 2025 in Review

Rock Springs Capital Management sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 150,020 shares — an estimated $2.93M sold.

Rock Springs Capital Management first reported a position in BEAM in Q2 2022 and held it in 12 quarters. The position peaked at $6.26M in Q4 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

Rock Springs Capital Management reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
Rock Springs Capital Management sold 150,020 Beam Therapeutics shares in Q2 2025, an estimated $2.93M.
Rock Springs Capital Management first reported a position in Beam Therapeutics in Q2 2022 and held it in 12 quarters.
Rock Springs Capital Management's Beam Therapeutics position peaked at $6.26M in Q4 2024.
217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.